Literature DB >> 8052419

Differential regulation of brain-derived neurotrophic factor and type II calcium/calmodulin-dependent protein kinase messenger RNA expression in Alzheimer's disease.

K D Murray1, C M Gall, E G Jones, P J Isackson.   

Abstract

The relative levels of messenger RNA for brain-derived neurotrophic factor and the alpha subunit of calcium/calmodulin-dependent protein kinase type II were examined in hippocampal sections from Alzheimer's diseased and age matched non-diseased brains by in situ hybridization histochemistry. Consistent with previous reports in monkey and rodent, calcium/calmodulin-dependent protein kinase II messenger RNA was prevalent throughout the dentate gyrus, all the principal hippocampal subfields, and adjacent cortical regions. A distribution consistent with the dendritic localization of calcium/calmodulin-dependent protein kinase II was also observed. In contrast, brain-derived neurotrophic factor messenger RNA levels were much lower than calcium/calmodulin-dependent protein kinase II messenger RNA levels and were less widely distributed. Within the hippocampus of Alzheimer's diseased brains, levels of calcium/calmodulin-dependent protein kinase II messenger RNA were increased and levels of brain-derived neurotrophic factor messenger RNA were decreased in comparison with matched controls. These changes were consistently seen in four out of six cases processed for both messenger RNA species and ranged from 150-300% relative to non-diseased brain tissue for calcium/calmodulin-dependent protein kinase II and 20-70% for brain-derived neurotrophic factor. These results suggest that within the Alzheimer's hippocampus an altered program of gene expression is occurring leading to aberrant levels of both calcium/calmodulin-dependent protein kinase II and brain-derived neurotrophic factor messenger RNA. Previous studies of the activity-dependent regulation of these messenger RNA species suggest these results are consistent with a decrease in afferent activity within the Alzheimer's hippocampus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8052419     DOI: 10.1016/0306-4522(94)90202-x

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  26 in total

1.  A transgenic mouse model engineered to investigate human brain-derived neurotrophic factor in vivo.

Authors:  Fabrice Guillemot; Italina Cerutti; Charles Auffray; Marie-Dominique Devignes
Journal:  Transgenic Res       Date:  2007-01-16       Impact factor: 2.788

2.  A high cholesterol diet given to apolipoprotein E-knockout mice has a differential effect on the various neurotrophin systems in the hippocampus.

Authors:  Zhi-Yu Wang; Takanori Miki; Yan Ding; Shi-Jie Wang; Yu-Huan Gao; Xiao-Ling Wang; Yu-Hua Wang; Toshifumi Yokoyama; Katsuhiko Warita; Ken-ichi Ohta; Shingo Suzuki; Taira Ohnishi; Takashi Obama; Kuldip S Bedi; Yoshiki Takeuchi; Bao-En Shan
Journal:  Metab Brain Dis       Date:  2011-08-09       Impact factor: 3.584

3.  Glial cell line-derived neurotrophic factor (GDNF) gene expression in the human brain: a post mortem in situ hybridization study with special reference to Parkinson's disease.

Authors:  S Hunot; V Bernard; B Faucheux; F Boissière; E Leguern; C Brana; P P Gautris; J Guérin; B Bloch; Y Agid; E C Hirsch
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Brain-derived neurotrophic factor (BDNF) and TrkB hippocampal gene expression are putative predictors of neuritic plaque and neurofibrillary tangle pathology.

Authors:  Stephen D Ginsberg; Michael H Malek-Ahmadi; Melissa J Alldred; Yinghua Chen; Kewei Chen; Moses V Chao; Scott E Counts; Elliott J Mufson
Journal:  Neurobiol Dis       Date:  2019-07-23       Impact factor: 5.996

5.  Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons.

Authors:  J C Lauterborn; G Lynch; P Vanderklish; A Arai; C M Gall
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

Review 6.  Estrogen-BDNF interactions: implications for neurodegenerative diseases.

Authors:  Farida Sohrabji; Danielle K Lewis
Journal:  Front Neuroendocrinol       Date:  2006-10-27       Impact factor: 8.606

Review 7.  Neurotrophins and the primate central nervous system: a minireview.

Authors:  M Hayashi
Journal:  Neurochem Res       Date:  1996-07       Impact factor: 3.996

Review 8.  Born to Protect: Leveraging BDNF Against Cognitive Deficit in Alzheimer's Disease.

Authors:  Lucia Caffino; Francesca Mottarlini; Fabio Fumagalli
Journal:  CNS Drugs       Date:  2020-03       Impact factor: 5.749

9.  Promoter IV-BDNF deficiency disturbs cholinergic gene expression of CHRNA5, CHRM2, and CHRM5: effects of drug and environmental treatments.

Authors:  Kazuko Sakata; Abigail E Overacre
Journal:  J Neurochem       Date:  2017-08-16       Impact factor: 5.372

10.  Involvement of BDNF in age-dependent alterations in the hippocampus.

Authors:  Oliver von Bohlen und Halbach
Journal:  Front Aging Neurosci       Date:  2010-08-13       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.